AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9777793 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene-UVB treatment (tazarotene 0.1% gel once daily for 2 weeks followed by tazarotene plus UVB therapy 3 times per week for 10 weeks)
Number of subjects: 0
Study 9777793 — intervention group
Group type: COMPARATOR
Intervention: UVB therapy alone
Number of subjects: 0
Study 9777793 — intervention group
Group type: COMPARATOR
Intervention: UVB therapy plus vehicle gel
Number of subjects: 0
Study 7817163 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml (0.1 mg) fentanyl intravenously
Number of subjects: 56
Study 7817163 — intervention group
Group type: COMPARATOR
Intervention: 2 ml saline intravenously
Number of subjects: 56
Study 2802431 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-monitor group (n = 23)
Number of subjects: 50
Study 2802431 — intervention group
Group type: COMPARATOR
Intervention: Clinic group (n = 23)
Number of subjects: 50
Study 2802431 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 2802431 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-monitor group
Number of subjects: 50
Study 1106278 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 38
Study 1106278 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 38
Study 1106278 — intervention group
Group type: COMPARATOR
Intervention: Prednisone only
Number of subjects: 38
Study 30056747 — intervention group
Group type: EXPERIMENTAL
Intervention: Melodic Intonation Therapy (12 sessions over six weeks)
Number of subjects: 20
Study 30056747 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control (no treatment initially)
Number of subjects: 20
Study 28654363 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention (n = 19,541)
Number of subjects: 48835
Study 28654363 — intervention group
Group type: COMPARATOR
Intervention: Usual diet comparison (n = 29,294)
Number of subjects: 48835
Study 26790209 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep needling
Number of subjects: 50
Study 26790209 — intervention group
Group type: COMPARATOR
Intervention: Shallow needling
Number of subjects: 50
Study 23940216 — intervention group
Group type: EXPERIMENTAL
Intervention: cediranib (30 mg) monotherapy
Number of subjects: 325
Study 23940216 — intervention group
Group type: EXPERIMENTAL
Intervention: cediranib (20 mg) plus lomustine (110 mg/m(2))
Number of subjects: 325
Study 23940216 — intervention group
Group type: COMPARATOR
Intervention: lomustine (110 mg/m(2)) plus placebo
Number of subjects: 325
Study 23940216 — intervention group
Group type: EXPERIMENTAL
Intervention: cediranib (30 mg) monotherapy and cediranib (20 mg) plus lomustine
Number of subjects: 325
Study 16627149 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail administration of SF-36 and Oxford Hip questionnaires
Number of subjects: 99
Study 16627149 — intervention group
Group type: COMPARATOR
Intervention: Interview administration of SF-36 and Oxford Hip questionnaires
Number of subjects: 99
Study 16627149 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidity analysis
Number of subjects: 99
Study 16627149 — intervention group
Group type: EXPERIMENTAL
Intervention: Age analysis
Number of subjects: 99
Study 14510037 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (DMI) + Contingency Management (CM)
Number of subjects: 149
Study 14510037 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (DMI) + Noncontingency Management (NCM)
Number of subjects: 149
Study 14510037 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Contingency Management (CM)
Number of subjects: 149
Study 14510037 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Noncontingency Management (NCM)
Number of subjects: 149
Study 10467973 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium augmentation
Number of subjects: 76
Study 8605789 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (maximum of 1 mg in double-blind phase, up to 2.5 mg in open phase)
Number of subjects: 110
Study 8605789 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.7 +/- 0.3 mg)
Number of subjects: 110
Study 8605789 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 110
Study 1874931 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg elemental calcium/day
Number of subjects: 295
Study 1874931 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 mg elemental calcium/day
Number of subjects: 295
Study 1874931 — intervention group
Group type: COMPARATOR
Intervention: Control group (no calcium supplementation)
Number of subjects: 295
Study 1874931 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (both doses)
Number of subjects: 295
Study 7045659 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole plus aspirin
Number of subjects: 407
Study 7045659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 407
Study 31371315 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dacarbazine (DTIC) administered at 850 mg/m2 intravenously on days 1 and 28, and interferon‐alpha‐2b (IFN‐α‐2b) administered at 3 million units three times a week subcutaneously for 24 weeks beginning at week 9.
Number of subjects: 33
Study 31371315 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dacarbazine (DTIC) and interferon‐alpha‐2b (IFN‐α‐2b)
Number of subjects: 33
Study 31371315 — intervention group
Group type: COMPARATOR
Intervention: Observation group (eligible but not enrolled patients)
Number of subjects: 33
Study 30149135 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri (2 × 10^8 CFU, twice daily during antibiotic treatment)
Number of subjects: 250
Study 30149135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 27935085 — intervention group
Group type: COMPARATOR
Intervention: 70% 1-repetition maximum (1RM)
Number of subjects: 10
Study 27935085 — intervention group
Group type: EXPERIMENTAL
Intervention: 90% 1-repetition maximum (1RM)
Number of subjects: 10
Study 26455249 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling group (written instruction + monthly counselling)
Number of subjects: 240
Study 26455249 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling group
Number of subjects: 240
Study 26455249 — intervention group
Group type: COMPARATOR
Intervention: Control group (written instruction only)
Number of subjects: 240
Study 26455249 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 240
Study 23791497 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional + modified ultrafiltration (MUF) (CM) group
Number of subjects: 65
Study 23791497 — intervention group
Group type: COMPARATOR
Intervention: Prime + zero‐balanced + MUF (PZM) group
Number of subjects: 65
Study 21545190 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection of methylprednisolone acetate 40 mg/mL with 0.8 mL lidocaine plus injection of 1 mL hyaluronic acid 0.8% 10 days later (n=15; group A)
Number of subjects: 30
Study 21545190 — intervention group
Group type: COMPARATOR
Intervention: Open surgical release of the first annular pulley (n=15; group B)
Number of subjects: 30
Study 18467278 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions for antisocial personality disorder (ASPD)
Number of subjects: 0
Study 18467278 — intervention group
Group type: EXPERIMENTAL
Intervention: Correctional practices
Number of subjects: 0
Study 16634495 — intervention group
Group type: EXPERIMENTAL
Intervention: Early loading of implants (< or = 14 days postimplantation)
Number of subjects: 24
Study 16634495 — intervention group
Group type: COMPARATOR
Intervention: Standard loading of implants (3 to 4 months postimplantation)
Number of subjects: 24
Study 14663805 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonography
Number of subjects: 47
Study 14663805 — intervention group
Group type: COMPARATOR
Intervention: Axiography
Number of subjects: 47
Study 10966244 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative cultures obtained by bronchoscopic or nonbronchoscopic techniques (Group A)
Number of subjects: 91
Study 10966244 — intervention group
Group type: COMPARATOR
Intervention: Nonquantitative tracheal aspirates cultures based on clinical judgment (Group B)
Number of subjects: 91
Study 10966244 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 91
Study 10966244 — intervention group
Group type: EXPERIMENTAL
Intervention: Days of mechanical ventilation
Number of subjects: 91
Study 10966244 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU stay
Number of subjects: 91
Study 8695094 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural PCA (EPCA) with sufentanil: 0.3 microgram/kg bolus followed by 8 micrograms/hr infusion plus epidural PCA boluses of 4 micrograms every 6 min as needed
Number of subjects: 29
Study 8695094 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. PCA with sufentanil: 0.3 microgram/kg bolus followed by 8 micrograms/hr infusion plus IV PCA boluses of 4 micrograms every 6 min as needed
Number of subjects: 29
Study 8695094 — intervention group
Group type: COMPARATOR
Intervention: i.v. PCA with morphine: 0.1 mg/kg bolus followed by 0.5 mg/hr infusion plus i.v. PCA boluses of 1 mg every 6 min as needed
Number of subjects: 29
Study 1739528 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD mode
Number of subjects: 16
Study 1739528 — intervention group
Group type: COMPARATOR
Intervention: VVI mode
Number of subjects: 16
Study 1739528 — intervention group
Group type: COMPARATOR
Intervention: DDI mode
Number of subjects: 16
Study 6686121 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised walking-programme
Number of subjects: 108
Study 31129600 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit and up to six telephone health-coaching sessions
Number of subjects: 86
Study 31129600 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 86
Study 29432857 — intervention group
Group type: EXPERIMENTAL
Intervention: intensive antiretroviral treatment strategy
Number of subjects: 368
Study 29432857 — intervention group
Group type: COMPARATOR
Intervention: standard antiretroviral treatment strategy
Number of subjects: 368
Study 29432857 — intervention group
Group type: EXPERIMENTAL
Intervention: interruption of treatment
Number of subjects: 368
Study 29432857 — intervention group
Group type: COMPARATOR
Intervention: continuation of treatment
Number of subjects: 368
Study 26829102 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedles (MNs) of 500μm or 750μm length, in arrays containing 10 or 50 MNs
Number of subjects: 28
Study 24589573 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal debridement using a sterile #15 blade on a Bard-Parker handle
Number of subjects: 120
Study 24589573 — intervention group
Group type: COMPARATOR
Intervention: Conjunctival swabs only (Control Group)
Number of subjects: 120
Study 22906371 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-anchored maxillary expander (BAME) treatment
Number of subjects: 42
Study 22906371 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 42
Study 22906371 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 42
Study 21046863 — intervention group
Group type: EXPERIMENTAL
Intervention: Ten minute medication review by a general practitioner
Number of subjects: 50
Study 17373899 — intervention group
Group type: EXPERIMENTAL
Intervention: Human papillomavirus vaccine
Number of subjects: 0
Study 16485865 — intervention group
Group type: EXPERIMENTAL
Intervention: Health advocacy, counseling, and activation program (16 lectures, 8 group discussions, 6 exercise sessions, 3 social activities)
Number of subjects: 227
Study 16485865 — intervention group
Group type: EXPERIMENTAL
Intervention: Health advocacy, counseling, and activation program
Number of subjects: 227
Study 16485865 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 227
Study 11903235 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine for 4 months
Number of subjects: 0
Study 11903235 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine for 3 months
Number of subjects: 0
Study 11903235 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole for 4 months
Number of subjects: 0
Study 11903235 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole for 3 months
Number of subjects: 0
Study 7782463 — intervention group
Group type: EXPERIMENTAL
Intervention: Exner administration
Number of subjects: 20
Study 7782463 — intervention group
Group type: EXPERIMENTAL
Intervention: first Exner administration
Number of subjects: 20
Study 7782463 — intervention group
Group type: COMPARATOR
Intervention: Rapaport administration
Number of subjects: 20
Study 2184796 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose levothyroxine sodium added to a stable regimen of medications
Number of subjects: 11
Study 2184796 — intervention group
Group type: COMPARATOR
Intervention: Placebo substitution (single- or double-blind)
Number of subjects: 11
Study 424377 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped Care
Number of subjects: 11237
Study 424377 — intervention group
Group type: COMPARATOR
Intervention: Referred Care
Number of subjects: 11237
Study 31615585 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride (1 mg)
Number of subjects: 41
Study 31615585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 31012498 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive distal pancreatectomy (laparoscopic)
Number of subjects: 104
Study 31012498 — intervention group
Group type: COMPARATOR
Intervention: Open distal pancreatectomy
Number of subjects: 104
Study 29149915 — intervention group
Group type: EXPERIMENTAL
Intervention: Safewards intervention
Number of subjects: 565
Study 25410983 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-mediated PDT (20% ALA solution, 1.5 h incubation, 630 nm red light, 80 J/cm(2))
Number of subjects: 26
Study 25410983 — intervention group
Group type: COMPARATOR
Intervention: Red light alone
Number of subjects: 26
Study 24330570 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer training (12 weeks, 2-3 times/week for 45-60 min)
Number of subjects: 80
Study 24330570 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer training
Number of subjects: 80
Study 24330570 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 80
Study 22032998 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 31
Study 22032998 — intervention group
Group type: COMPARATOR
Intervention: Control (no kinesio taping)
Number of subjects: 31
Study 19858394 — intervention group
Group type: EXPERIMENTAL
Intervention: VMP (bortezomib 1.3 mg/m², melphalan 9 mg/m², prednisone 60 mg/m²)
Number of subjects: 227
Study 19858394 — intervention group
Group type: COMPARATOR
Intervention: MP (melphalan and prednisone)
Number of subjects: 227
Study 19858394 — intervention group
Group type: EXPERIMENTAL
Intervention: VMP
Number of subjects: 227
Study 19858394 — intervention group
Group type: COMPARATOR
Intervention: MP
Number of subjects: 227
Study 17118098 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral electrical nerve stimulation
Number of subjects: 62
Study 17118098 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (placebo)
Number of subjects: 62
Study 15659884 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary adherence intervention
Number of subjects: 68
Study 11712719 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session music therapy interventions
Number of subjects: 80
Study 9024176 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg
Number of subjects: 6
Study 9024176 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 20 mg
Number of subjects: 6
Study 9024176 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 100 mg
Number of subjects: 6
Study 9024176 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 250 mg
Number of subjects: 6
Study 9024176 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 40 mg
Number of subjects: 6
Study 9024176 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 200 mg
Number of subjects: 6
Study 9024176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8127465 — intervention group
Group type: EXPERIMENTAL
Intervention: Optokinetic stimulation (OKS) with velocities ranging from -100 to +100 degree/sec
Number of subjects: 10
Study 8127465 — intervention group
Group type: EXPERIMENTAL
Intervention: Optokinetic stimulation (OKS) with upward velocities
Number of subjects: 10
Study 3722374 — intervention group
Group type: EXPERIMENTAL
Intervention: Air at body conditions during exercise
Number of subjects: 17
Study 3722374 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing heat content of air during recovery
Number of subjects: 17
Study 3722374 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlling ventilation during recovery from hyperventilation of frigid air
Number of subjects: 17
Study 3722374 — intervention group
Group type: COMPARATOR
Intervention: Frigid air inhalation during exercise
Number of subjects: 17
Study 31923161 — intervention group
Group type: EXPERIMENTAL
Intervention: Progrip (PG)
Number of subjects: 150
Study 31923161 — intervention group
Group type: COMPARATOR
Intervention: Fibrin Sealant (FS)
Number of subjects: 150
Study 28991119 — intervention group
Group type: EXPERIMENTAL
Intervention: High operating table at xiphoid process (group X)
Number of subjects: 60
Study 28991119 — intervention group
Group type: EXPERIMENTAL
Intervention: High operating table at nipple level (group N)
Number of subjects: 60
Study 28991119 — intervention group
Group type: COMPARATOR
Intervention: High operating tables at umbilicus (group U) and lowest rib margin (group R)
Number of subjects: 60
Study 28991119 — intervention group
Group type: EXPERIMENTAL
Intervention: High operating tables (groups X and N)
Number of subjects: 60
Study 26620100 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentionally high restorations (0.5mm supraocclusion)
Number of subjects: 17
Study 26620100 — intervention group
Group type: COMPARATOR
Intervention: Control group with restorations without intentional increase of occlusal vertical dimension
Number of subjects: 17
Study 24402888 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapler transection
Number of subjects: 130
Study 24402888 — intervention group
Group type: COMPARATOR
Intervention: Clamp-crushing
Number of subjects: 130
Study 24402888 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 130
Study 22566113 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral probiotics
Number of subjects: 221
Study 22566113 — intervention group
Group type: COMPARATOR
Intervention: Control group (no probiotics)
Number of subjects: 221
Study 20517212 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrostimulation
Number of subjects: 42
Study 20517212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 18442104 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalamic stimulation
Number of subjects: 68
Study 18442104 — intervention group
Group type: COMPARATOR
Intervention: Thalamotomy
Number of subjects: 68
Study 15918060 — intervention group
Group type: EXPERIMENTAL
Intervention: Open‐circuit acetylene uptake (OpCirc)
Number of subjects: 13
Study 15918060 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐breath acetylene uptake (SB)
Number of subjects: 13
Study 15918060 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 rebreathing (CO2RB)
Number of subjects: 13
Study 12483234 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) 0.2%
Number of subjects: 14
Study 12483234 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix protein derivative (EMD)
Number of subjects: 14
Study 12483234 — intervention group
Group type: EXPERIMENTAL
Intervention: Propylene glycol alginate (PGA)
Number of subjects: 14
Study 12483234 — intervention group
Group type: EXPERIMENTAL
Intervention: 24% Ethylenediaminetetra-acetate (EDTA)
Number of subjects: 14
Study 12483234 — intervention group
Group type: COMPARATOR
Intervention: Saline (NaCl)
Number of subjects: 14
Study 10529124 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A 2.5 mg/kg/day
Number of subjects: 244
Study 10529124 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine A 1.5 mg/kg/day
Number of subjects: 244
Study 10529124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 7720447 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback therapy
Number of subjects: 16
Study 7720447 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 16
Study 2183346 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (Fuji III)
Number of subjects: 20
Study 2183346 — intervention group
Group type: COMPARATOR
Intervention: Diluted composite (Control)
Number of subjects: 20
Study 6753707 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 29
Study 6753707 — intervention group
Group type: COMPARATOR
Intervention: Diphenoxylate
Number of subjects: 29
Study 6388523 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride
Number of subjects: 61
Study 29493047 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin treatment group
Number of subjects: 980
Study 27759816 — intervention group
Group type: EXPERIMENTAL
Intervention: FP Group (fentanyl 1mcg/kg and propofol 1.5mg/kg)
Number of subjects: 61
Study 27759816 — intervention group
Group type: COMPARATOR
Intervention: MRPB Group (midazolam 0.075mg/kg and remifentanil 0.25mcg/kg/min with paracervical block with 3mL of 2% lidocaine)
Number of subjects: 61
Study 23639070 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory training (adaptive n-back training, 12 sessions)
Number of subjects: 60
Study 23639070 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory training (adaptive n-back training)
Number of subjects: 60
Study 22499839 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent placement for extracranial ICA stenosis
Number of subjects: 59
Study 22499839 — intervention group
Group type: COMPARATOR
Intervention: Normal CirT (control group)
Number of subjects: 59
Study 20525323 — intervention group
Group type: EXPERIMENTAL
Intervention: Seattle Angina Questionnaire (SAQ) scales: Exertional Capacity Scale (ECS), Disease Perception Scale (DPS), Anginal Frequency Scale (AFS)
Number of subjects: 0
Study 20525323 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic variables (age, gender, disease stage)
Number of subjects: 0